Dihexa--5mg 10mg 15mg 20mg Spot goods

Glutathione

Glycine,L-γ-glutamyl-L-cysteinyl-;Glutathione;Glycine,N-(N-L-γ-glutamyl-L-cysteinyl)-;L-γ-Glutamyl-L-cysteinylglycine;γ-L-Glutamyl-L-cysteinylglycine;Glutathione-SH;GSH;L-Glutathione;Reduced glutathione;Triptide;Glutide;Tathion;Tathione;Copren;Deltathione;Glutathion;Glutinal;Isethion;Neuthion;Agifutol S;γ-Glutamylcysteinylglycine;N-(N-L-γ-Glutamyl-L-cysteinyl)glycine;Bakezyme RX;ReadiSorb;Atomolan;High Thione Extract YH 15;N5-((R)-1-((Carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)-L-glutamine;TAD 600;1109226-07-4;1655518-50-5

70-18-8

C10H17N3O6S

InChIKey=RWSXRVCMGQZWBV-WDSKDSINSA-N

307.32300

307.32

200-725-4

GAN16C9B8O

758199

DTXSID6023101

C523

V - Various

2930909090

Bulk Drug Intermediates

197.62000

-4.5

Solid

1.441 g/cm3

195 °C

410.1ºC

410.1±32.9 °C

1.571

H2O: 292.5 mg/mL

2-8ºC

167.4 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|168.23 Ų [M+Na]+ [CCS Type: DT, Method: stepped-field]|164.24 Ų [M-H]- [CCS Type: DT, Method: stepped-field]|165 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine]|167.8 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|167 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|162.1 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|164.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|165.7 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]|164.8 Ų [M-2H+Na]-

Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator

Research compound — Not FDA approved

A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.

65 pM

Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).

Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.

NCT04488419

PubChem

9WYX65A5C2

Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status

Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.